ArticleHealth science reports2025
The Predictive Significance of Various Prognostic Scoring Systems on the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients: A Retrospective Study.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integrated multi-dataset screening to predict prognosis and identify immunotherapy gene targets in hepatocellular carcinoma patients.Scientific reports · 2026Article
- Comparative predictive value of immunotherapy biomarkers: a systematic review and network meta-analysis.International journal of surgery (London, England) · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: To evaluate the efficacy and prognostic value of various immunoprognostic scoring systems-Lung Immune Prognostic Index (LIPI), modified Glasgow Prognostic Score (mGPS), and Gustave Roussy Immune Score (GRIm)-in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs). Methods: We conducted a retrospective analysis of clinical data from 219 NSCLC patients treated with ICIs at Zhongshan Hospital (Xiamen), Fudan University from June 1, 2019 to January 31, 2024. The therapeutic efficacy and predictive capabilities of the scoring systems were assessed using Kaplan-Meier curves, Cox proportional hazards models, time-dependent ROC curves, and random survival forest models. Results: The median follow-up was 29 months (IQR: 25.96-32.04), resulting in 93 observed deaths. Both LIPI and GRIm scores correlated with declining overall survival (OS) and progression-free survival (PFS) as risk levels increased. LIPI demonstrated superior predictive performance at 12, 24, and 36 months (AUC: 0.70, 0.62, 0.61, respectively). Multivariate analysis identified immune-related adverse events (irAEs) and lactate dehydrogenase (LDH) levels as independent prognostic factors for OS. Conclusion: LIPI serves as an effective prognostic tool for NSCLC patients receiving immunotherapy, outperforming individual inflammatory markers. Additionally, irAEs and LDH levels are significant independent prognostic factors for OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.